Key facts
- NovAccel’s last known valuation is $15.1M (Aug 2025).
- It has raised $6.3M; the latest was Seed Round ($6.3M) in Aug 2025.
- Notable investors include The University of Tokyo Edge Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NovAccel
- ·The full record, as it builds
Funding rounds
No funding rounds for NovAccel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovAccel
Developer of accelerator technology for cancer treatment intended to create a future where cancer is curable. The company offers the development of medical radioisotopes and joint research and development, aiming to improve cancer treatment through innovative accelerator technology, enabling healthcare professionals to develop new cancer treatments.
- Sector
- Healthcare
- HQ
- Tsukuba, Japan
- Founded
- 2024
- Website
- novaccel.jp/
- Ownership
- Privately Held (backing)
NovAccel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovAccel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovAccel in its N-PORT filings yet. We sweep new filings monthly.